Long-term Effects of P2Y12 Inhibitor Monotherapy After Percutaneous Coronary Intervention

This 3-year follow-up of a randomized clinical trial assesses the long-term safety and efficacy of P2Y12 inhibitor monotherapy following 3 months of dual antiplatelet therapy after percutaneous coronary intervention.

Read the full article here

Related Articles